Healthcare providers share insights about GENAYA for young adult cancer patients
In a series of short videos, our specialists share their insights on the GENAYA project. They explain what GENAYA is, how it works in practice, and why they chose to participate. They also discuss how patients respond to participation and how the project can be effectively integrated into regional hospitals. Discover in this article what GENAYA means for healthcare providers and patients alike.
The Patient of Today
Medical oncologist Rhodé Bijlsma from UMC Utrecht explains why GENAYA is important for cancer patients aged 18-39. She also shares how she and her colleagues at UMC Utrecht are doing their best to get as many patients as possible to participate in the project. Not only can patients be referred by their medical oncologist, but also by their surgeon, gynaecologist, pulmonologist, or neurologist.
The Patient of Tomorrow
Winette van der Graaf, medical oncologist at the Netherlands Cancer Institute, explains why GENAYA is so important for future patients: “It’s incredibly important to gather more data from young patients because most of the knowledge we have about cancer has been primarily gathered from older patients. We believe that younger patients might have genetically different tumors.” She emphasizes that we can only make progress if we conduct thorough research, not just here, but worldwide.
The Patient in the Regional Hospital
Nurse Specialist Wies Tönis and medical oncologist Annelieke Willems talk about the care for young cancer patients at Tergooi MC. The GENAYA project plays an important role in this. Tergooi MC collaborates with all the hospitals in the region, maintaining close connections with each other. This allows them to easily consult with colleagues to find the best treatment for the patient, whether at Tergooi or elsewhere. Wies Tönis discusses the support provided to AYA (Adolescents and Young Adults) patients and how participation in GENAYA works in practice.
Want to know more?
- Watch all videos (in Dutch)
All news
Also read
To study rare cancers, collaboration is key
In honor of Rare Disease Day on February 28th, we spoke with Professor Stefan Fröhling about his research on rare …
Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing …
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
It is essential to record and share data to ensure good care.